SPANXA1 is a cancer/testis (CT) antigen that plays important roles in spermatogenesis and cancer biology. During normal male reproduction, SPANXA1 localizes to the nuclear envelope of spermatids in non-acrosomal domains and redistributes to the redundant nuclear envelope during spermiogenesis, serving as a biomarker for these cellular structures 1. The protein is normally expressed only in testis among mature tissues, making it highly immunogenic 2. In cancer contexts, SPANXA1 functions as an oncogene, with hypomethylation-driven overexpression promoting metastasis in head and neck squamous cell carcinoma through epithelial-mesenchymal transition (EMT) pathways 3. The gene is upregulated by histone H3.3K27M mutations in pediatric gliomas 4 and shows preferential expression in cancer stem-like cells, supporting the novel cancer/testis/stem (CTS) gene classification 5. SPANXA1 expression correlates with poor patient survival and increased metastatic potential, while knockdown inhibits cancer cell migration and invasion 3. Its restricted normal expression pattern and immunogenicity make it a promising target for cancer immunotherapy, with detectable antibody responses observed in patients with hematologic malignancies 2 and potential utility as a diagnostic biomarker for prostate cancer 6.